Senseonics Holdings, Inc. (NASDAQ:SENS) Expected to Announce Quarterly Sales of $6.14 Million

Wall Street analysts expect Senseonics Holdings, Inc. (NASDAQ:SENS) to post $6.14 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Senseonics’ earnings, with the highest sales estimate coming in at $6.46 million and the lowest estimate coming in at $5.67 million. Senseonics posted sales of $5.16 million in the same quarter last year, which suggests a positive year over year growth rate of 19%. The firm is scheduled to issue its next earnings report on Thursday, November 14th.

According to Zacks, analysts expect that Senseonics will report full-year sales of $27.21 million for the current financial year, with estimates ranging from $26.62 million to $27.54 million. For the next year, analysts anticipate that the company will post sales of $51.26 million, with estimates ranging from $43.63 million to $60.47 million. Zacks’ sales averages are an average based on a survey of sell-side research analysts that cover Senseonics.

Senseonics (NASDAQ:SENS) last announced its earnings results on Wednesday, August 7th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.01). The business had revenue of $4.61 million for the quarter, compared to the consensus estimate of $4.52 million.

SENS traded down $0.02 on Tuesday, hitting $1.06. 3,516,610 shares of the company’s stock were exchanged, compared to its average volume of 1,807,491. Senseonics has a fifty-two week low of $0.92 and a fifty-two week high of $4.89. The firm has a 50-day moving average price of $1.07 and a 200-day moving average price of $1.84.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days.

Read More: Is a Roth IRA right for you?

Get a free copy of the Zacks research report on Senseonics (SENS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with's FREE daily email newsletter.